Didactic Med · Hematology Atlas

Blood Disorders Decoded

An interactive reference to the diseases of red cells, coagulation, myeloid proliferation, and white-cell biology — built for clinicians at the bedside.

ASH 2024NCCN 2026ISTH 2025WHO-HEM5

Important Medical Disclaimer

Educational Purpose Only

This tool is designed exclusively for educational purposes to assist healthcare professionals in understanding hematological conditions and blood disorders. It is NOT intended to replace clinical judgment, professional medical education, institutional protocols, or direct patient care decisions.

Not a Diagnostic or Treatment Tool

  • No Self-Diagnosis: This tool should never be used for self-diagnosis or self-treatment by patients or non-healthcare professionals.
  • Clinical Correlation Required: All diagnoses must be made by qualified healthcare professionals after appropriate clinical evaluation and diagnostic testing.
  • Not Treatment Guidance: While medication information is provided, all treatment decisions must be made by licensed healthcare providers based on individual patient factors, allergies, contraindications, and current clinical guidelines.

Healthcare Professional Use Only

  • This tool is intended for use by licensed physicians, medical students, residents, nurses, and other qualified healthcare professionals.
  • Users must have appropriate medical training to interpret the information presented.
  • Always verify information with current authoritative sources and institutional protocols.

Medication Information Warning

  • Dosages and medication recommendations are for educational reference only.
  • Always verify dosing, check for drug interactions, confirm appropriateness for patient-specific factors, and consult current prescribing information before administering any medication.
  • Consider renal/hepatic function, pregnancy status, and other contraindications.
  • Pay particular attention to medications recently withdrawn from market or with new black-box warnings.

Professional Responsibility

  • Users of this tool are responsible for their own clinical decisions and actions.
  • Always practice within your scope of practice and institutional guidelines.
  • Consult hematology specialists when indicated and appropriate.
  • Document all clinical findings and decision-making processes appropriately.
  • Stay updated with current evidence-based guidelines and best practices.

No Liability

The creators, authors, and distributors of this tool assume no liability for any errors, omissions, or adverse outcomes resulting from the use of this information. Users assume full responsibility for all clinical decisions and their consequences.

Anemias
Coagulation
Myeloproliferative
WBC Disorders
Clinical safety update added during Tri-Lens review

Audit note for this tool: The following guardrails were added to reduce overconfidence and align with current educational CDS expectations.

  • This is an educational reference. Diagnoses, dosing, and disposition must be confirmed against current society guidance, institutional protocols, and individual patient context.
  • Voxelotor (Oxbryta) was voluntarily withdrawn worldwide on September 25, 2024 by Pfizer and is no longer recommended; the FDA issued a corresponding alert on September 26, 2024. The medication entry is retained in this atlas with a clear withdrawn marker for educational continuity only.
  • For oncologic and high-risk hematologic disease (acute leukemia, aggressive lymphoma, multiple myeloma, MDS, MPN with thrombosis), defer to specialty hematology/oncology consultation, current NCCN guidance, and institutional protocols.
  • For thrombotic emergencies (TTP, DIC, HIT, catastrophic APS), follow ISTH and ASH guidance; do not delay PLEX, anticoagulation, or critical care escalation.
  • Pre-treatment screening (TB, HBV, HCV, vaccinations, fertility counseling) and ongoing surveillance are integral to safe biologic and immunosuppressive use.

These guardrails supplement the original content and should be reconciled with current specialty guidance and local institutional policy.